Drug intelligence / Profile preview

BM306

Development stage: Unknown
Lead developer: Notitia Biotechnologies
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

BM306 is an investigational microbiome therapeutic from Notitia Biologics composed of a defined consortium of live Foundation Guild bacteria intended to restore missing or extinct core gut microbial species in patients. The product is being developed as a live biotherapeutic product therapy for disorders linked to microbiome disruption, with reported programs in functional gastrointestinal disorder in Long COVID-19, multiple sclerosis, Parkinson's disease, early and end-stage diabetic kidney disease, side-effects of cancer chemotherapy, and Prader-Willi syndrome. Its proposed mechanism is microbiome restoration and ecosystem reconstitution rather than a single named molecular target, and the most advanced disclosed program is Phase 2 in FGID in Long COVID-19.

Other names: Foundation Guild bacteria defined consortium

Beyond the preview

Go deeper on BM306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM306.

Explore the full profile